Delivery Order SPE2DB22D3016-SPE2DB25FAAK6

Award Date 10/10/24
Potential Completion Date 10/11/24
Potential Value $12K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,124.75, is for the supply of GARDASIL 9 syringes, a vaccine product. The contract has a firm fixed-price pricing structure and a completion date of November 29, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The $13,051.22 firm-fixed-price contract is for the supply of GARDASIL 9 syringes, a vaccine product. The delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999, for providing a comprehensive range of medical commodities to support military treatment...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $14,063.55 contract is for the supply of GARDASIL 9 syringes, a vaccine product, with a period of performance through August 2024. This delivery order appears to be part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued up to $999,999,999 and running through December 2025, for...
This is a $16,489.96 delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of GARDASIL 9 syringes, a vaccine product, to support military treatment programs and facilities. The contract has an ultimate completion date of July 30, 2024 and is a firm fixed-price arrangement. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $13,394.37 contract is for the delivery of GARDASIL 9 vaccine syringes to support military treatment programs and facilities. This delivery order is issued under an indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp, which has a total...
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,088.01, is for the delivery of GARDASIL 9 syringes (0.5mL) with a completion date of November 18, 2024. The contract is a delivery order under AmerisourceBergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
This is a $32,096.81 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of GARDASIL 9 vaccine syringes. The contract has a period of performance through February 4, 2025 and is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999. The IDC serves as a primary vehicle for AmerisourceBergen to provide a comprehensive range of pharmaceutical products and...
This is a $19,782.56 firm-fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of GARDASIL 9 syringes, a vaccine product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999, which enables the DLA to efficiently procure a wide range of medical commodities from AmerisourceBergen to support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of GARDASIL 9 syringes. The delivery order, valued at $13,463.75, has a firm fixed price and an ultimate completion date of September 24, 2024. The contract is not set aside for any particular business type. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for $9,788.44 to supply GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a period of performance through February 2025. The contract was awarded on a firm-fixed price basis without a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
  • SPE2DB22D3016
    Indefinite Delivery Contract
  • SPE2DB22D3016-SPE2DB25FAAK6
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the supply of GARDASIL 9 syringes, a vaccine product, valued at $11,523.25. The delivery order falls under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. This contract award does not utilize a set-aside designation. The contract has a firm fixed price pricing type and an ultimate completion date of October 11, 2024.

Generated 1/9/25, 9:18 AM